Clinical trials: Diabetes Prevention
Hyperlipidemias, Atherosclerosis
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy.
- Conditions
- Hyperlipidemias, Atherosclerosis, Coronary Heart Disease, Carotid Stenosis
- Trial name
- NCT00536965
- Where
- Austria
- Volunteers
- 951 people
- Sponsor
- AstraZeneca
PreDiabetes
Intestinimonas for Prevention of Type 2 Diabetes Mellitus
The study aims to assess the effects of a microbiota-based product containing Intestinimonas in adults with pre-diabetes. The purpose is to determine the safety and efficacy of the microbiota-based product on insulin sensitivity…
- Trial name
- NCT04495972
- Testing
- Intestinimonas-capsules
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Caelus Pharmaceuticals BV
Diabetes Mellitus, Type 1, Hypoglycemia
T1 Diabetes Hypoglycemia Prevention Pilot
A single center pilot study assessing the Vigilant Diabetes Management System for the prevention of recurrent mild to moderate hypoglycemia in type I diabetes patients.
- Trial name
- NCT02682940
- Testing
- Vigilant Diabetes Management Application
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- InSpark Technologies, Inc.
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes
The goal of this pragmatic trial is to provide Real World Evidence (RWE) on the impact of the result of a polygenic risk prediction test of cardiorenal complications of T2D, so that more patients at high risk of these…
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases, Diabetic Nephropathy Type 2
- Trial name
- GENOCORDIA (NCT06586203)
- Testing
- Polygenic Risk Score
- Where
- 2 sites in Canada
- Volunteers
- 2,714 people
- Sponsor
- Optithera
Cardiovascular Disease
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran based on US National Health and…
- Trial name
- NCT07214857
- Where
- United States
- Volunteers
- 1,385 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Diabetes
A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)
The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients.
- Trial name
- BENEDICT (NCT00235014)
- Testing
- trandolapril, trandolapril/verapamil, verapamil
- Volunteers
- 1,204 people
- Sponsor
- Abbott
Hypoglycemia, Diabetes Mellitus, Type 1
A Pilot Study of Nocturnal Hypoglycemia Prevention in Type 1 Diabetes Using the Vigilant Diabetes Management Companion
A single center pilot study assessing the Vigilant Diabetes Management Companion for the prevention of recurrent nocturnal hypoglycemia in type I diabetes patients.
- Trial name
- NCT02906891
- Testing
- Vigilant Diabetes Management Application
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- InSpark Technologies, Inc.
Plantar Ulcer, Diabetes
The CareFUL Prevention Trial
To assess the efficacy of TrueContour® Insoles versus the current standard of care insoles in recurrence of plantar MTH ulcers in men and women, 18 years of age or older at the time of consent with clinical diagnosis of Diabetes…
- Conditions
- Plantar Ulcer, Diabetes, Neuropathy Causing Loss of Protective Sensation
- Trial name
- CareFULPrevent (NCT00803608)
- Testing
- TrueContour® Insole, Current standard of care insole
- Where
- 11 sites in United States
- Volunteers
- 130 people
- Sponsor
- DIApedia, LLC
Hypercholesterolemia, Coronary Heart Disease
Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile…
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Peripheral Vascular Disease, Cerebrovascular Accident
- Trial name
- HEROS (NCT00660764)
- Testing
- Rosuvastatin
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Cardiovascular Disease
Olmesartan Medoxomil in Diabetes Mellitus
This is a study in diabetic patients with at least one additional cardiovascular risk factor and normoalbuminuria prior to randomization.
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Disease, Kidney Disease
- Trial name
- NCT00185159
- Testing
- Olmesartan medoxomil
- Where
- Germany
- Volunteers
- 4,449 people
- Sponsor
- Sankyo Pharma Gmbh
Major Coronary Event, Cerebrovascular Accident
CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy…
- Conditions
- Major Coronary Event, Cerebrovascular Accident, Coronary Artery Bypass Graft, Angina, Unstable
- Trial name
- CARDS (NCT00327418)
- Testing
- Atorvastatin
- Where
- 135 sites in United Kingdom
- Volunteers
- 2,800 people
- Sponsor
- Pfizer
Foot Ulcer, Diabetic
In-Home Assessment of a Smart Foot Mat for Prevention of Diabetic Foot Ulcers
The purpose of this study is to investigate the accuracy of a Smart Foot Mat for signals associated with diabetic foot ulcers in high-risk patients.
- Trial name
- NCT02647346
- Testing
- Daily use of podimetrics smart-foot mat
- Where
- 8 sites in United States
- Volunteers
- 132 people
- Sponsor
- Podimetrics, Inc.
Diabetic Retinopathy
Macular Edema Incidence/Severity Reduction With Nevanac
The purpose of this study is to evaluate NEVANAC in patients with diabetic retinopathy who developed macular edema (ME) within 90 days following cataract surgery.
- Trial name
- NCT00939276
- Testing
- Nepafenac ophthalmic suspension, 0.1% (NEVANAC®), Nepafenac ophthalmic suspension vehicle
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Alcon Research
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Overweight, Prediabetic State
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and…
- Conditions
- Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
- Trial name
- ATTAIN-NOW (NCT07794579)
- Testing
- Orforglipron
- Where
- 180 sites in United States, Argentina and 10 more
- Volunteers
- 2,001 people
- Sponsor
- Eli Lilly and Company
Diabetes, Pain Management
CGM as Diagnostic Tool in Observing Steroid-Induced Hyperglycemia
This study is designed to help understand how certain steroid medications affect blood sugar levels in patients undergoing pain management treatments.
- Trial name
- TRC-DX-1 (NCT06628284)
- Testing
- Dexcom G7
- Where
- 2 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Mahesh Pattabiraman
Type 2 Diabetes Mellitus
Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients
The objective was to evaluate the efficacy and safety of combination of beraprost and aspirin for prevention of arteriosclerosis progress in type 2 diabetes mellitus patients.
- Trial name
- NCT02786979
- Testing
- Beraprost, Aspirin
- Where
- 6 sites in China
- Volunteers
- 190 people
- Sponsor
- Astellas Pharma Inc
Diabetes, Ulceration
Shear and Pressure Reducing Insoles for the Diabetic Foot
We evaluated the feasibility of the GlideSoft™ novel insole to reduce pressure and shear forces on the foot. No commercially available insoles are designed to reduce shear.
- Conditions
- Diabetes, Ulceration, Amputation, Foot Deformity
- Trial name
- GlideSoft (NCT00499356)
- Testing
- pressure reducing insole, GlideSoft®
- Where
- United States
- Volunteers
- 299 people
- Sponsor
- Diabetica Solutions Inc.
Peripheral Arterial Disease (PAD), Moderate Risk for Cardiovascular Disease (CVD)
Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention
Non interventional study aimed to establish the prevalence of lower extremity peripheral arterial disease (PAD), defined as an ankle-brachial index (ABI) not above 0.90 in subjects with a moderate risk of cardiovascular disease…
- Trial name
- PANDORA (NCT00689377)
- Where
- 331 sites in Belgium, France and 4 more
- Volunteers
- 9,000 people
- Sponsor
- AstraZeneca
Type 1 Diabetes
Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes
A premarket, international multicenter, prospective, open label, adaptive, randomized controlled study. The aim is to evaluate the efficacy of sensor augmented pump therapy with MiniMed™640G and SmartGuard™in preventing…
- Trial name
- SMILE (NCT02733991)
- Testing
- MiniMed™640G and Suspend before low, MiniMed™640G
- Where
- 14 sites in France, Italy and 2 more
- Volunteers
- 153 people
- Sponsor
- Medtronic MiniMed, Inc.